Asset Value

Use evidence before assumptions harden.

RHIEOS works on the economics and value of clinical development: partner selection, budgets, contracts, payment models, participant burden and the scientific knowledge created along the way.

Part of the RHIEOS Decision to Value Loop

Partners: what should drive CRO and service-provider selection?

Economics: what range is defensible, and where is uncertainty concentrated?

Contracts: how do terms affect incentives, cost and delivery?

Knowledge ePV™: what can a programme learn even when the asset does not succeed?

Asset Value resources →

RHIEOS clinical research prototype showing CRO selection, CTA, participant burden and trial budget routes

RHIEOS Hypothesis Failure Premortem prototype

Real working artefacts: clinical-research routing across RHIEOS tools and a deliberately bounded hypothesis-failure prototype.

In practice

Two examples: budgets and selection.

Benchmarking R&D budgets across a global programme

For a global biopharma, RHIEOS built a multi-programme budget prediction and benchmarking model (TrialValue®) spanning 25 studies across Phases I–IV, several regions and therapeutic areas — turning fragmented per-study estimates into one comparable structure.

25Studies benchmarked

I – IVPhases covered

$0.25M – $83MBudget range modelled

Weeks → daysFinancial decision cycle

Learning: once budgets sit on one comparable structure, financial review compresses from a multi-week cycle to days.

Designing incentives for CRO selection

RHIEOS ran a pilot comparing a traditional RFP against a trust-based, mechanism-design multi-criteria approach, run in parallel across four service providers.

Traditional RFP

Opaque checklist evaluation
Capability and price dominate
Hidden risks emerge late
Longer renegotiation cycle

Trust-based mechanism design

Criteria configured around incentives and trust
Evidence normalised and weighted transparently
Hard filters remove non-viable options early
Decision logic stays transparent and auditable

12 wks → 2 wksTypical vs pilot decision time

49%Weight placed on trust

≥70%Hard compliance filter

4Service providers engaged

Learning: selection quality improves when decision rules are designed for transparency and early risk exposure.

Request the RfP MCA template →

Other areas

Part of the same loop.

AccessReducing trial burden, then broader patient and health-system access.AssuranceDecision rights, oversight and partnering across regulated and AI-supported work.LearningPurpose, goals, judgement, capability and organisational learning.